A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed 91 enrolled MorphoSys AG

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicentre, dose escalation study to characterize the safety and preliminary efficacy of the human anti-CD38 antibody MOR03087 (MOR202), in adult subjects with relapsed/refractory multiple myeloma, as monotherapy and in adult subjects with relapsed/refractory multiple myeloma in combination with standard therapy.

Timeline

Start: 2011-07
Primary completion: 2020-08
Completion: 2020-08

Publications

Raab MS, Engelhardt M, Blank A, Goldschmidt H, Agis H, Blau IW, Einsele H, Ferstl B, Schub N, Rollig C, Weisel K, Winderlich M, Griese J, Hartle S, Weirather J, Jarutat T, Peschel C, Chatterjee M. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Lancet Haematol. 2020 May;7(5):e381-e394. doi: 10.1016/S2352-3026(19)30249-2. Epub 2020 Mar 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dexamethasone	Small molecule	20 mg	Oral
Subject	Dexamethasone	Small molecule	40 mg	Oral
Subject	Felzartamab	Monoclonal antibody	0.01 mg/kg	Intravenous
Subject	Felzartamab	Monoclonal antibody	4 mg/kg	Intravenous
Subject	Felzartamab	Monoclonal antibody	8 mg/kg	Intravenous
Subject	Felzartamab	Monoclonal antibody	16 mg/kg	Intravenous
Subject	Lenalidomide	Other / unclassified	25 mg	Oral
Subject	Pomalidomide	Other / unclassified	4 mg	Oral

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications